





APPENDIX III

Form Template

All sections of the application form must be completely filled out for analysis.

1. Basic Information				
Name of the participating entity:				
Name of the requirement:				
Challenge to which the pro	oposal responds:	□ EQU	JILIN	
Acronym:				
Do you intend to submit to future tenders related to the challenge or challenges to which you are applying? 2. Participant's information				
Natural person:				
Legal person:				
Sector or field of activity (CNAE):				
Main activities of the company (Design, Manufacture, Sales, Distribution, etc.):				
Type of Entity (Self- employed, Private company, Public company, Research center, University, Technology center, Other):				
Year of incorporation:				
Joint response from several natural or legal persons: Tick YES or NO.	YES 🗆		NO 🗆	
Size of the entity at present (No. of persons on staff):				
Total turnover of the entity over the past 3 years (euros):	2019	2018		2017







3. Information on the Contact person/representative			
Contact Name (or representative in case of a joint response):			
Phone:			
Email address:			
Address:			
4. Additional information			
Has your company had any to technologies similar to those response over the past 3 year YES or NO.	se in this	YES 🗆	NO 🗆
If you answered YES to the above, please indicate the apturnover for technologies similar this response over the pas (aggregate data for the 3 years)	oproximate to those in t 3 years		
Do you think your entity holds the certifications to fulfill the require out? Answer YES or NO.		YES □	NO 🗆
If you answered YES to the above, please indicate who certifications are (max. 300 char	hat these		
Do you think your staff qualifications that are specificato fulfill the requirements set of YES or NO.	Illy relevant	YES □	NO 🗆
If you answered YES to the above, please indicate who qualifications are (max. 300 characters)	hat those		
Does your entity have expended executing projects in the field Intelligence, Artificial Vision, A Reality? Answer YES or NO.	of Artificial	YES □	NO 🗆
If you answered YES to the above, please indicate a brief s the experience (scope, client, execution and brief description)	summary of period of		
Have you made an investmen the last 3 years? Answer YES or N		YES □	NO 🗆







If you answered YES to the question above, please indicate the amount of this investment in the last 3 years (grouped data from the 3 years)			
Indicate the technological capabilities you have to face the development of new innovative solutions:			
Has your entity obtained public financing of competitive competition for R&D projects in any of the last 3 years ?: Answer YES or NO.	YES □	NO 🗆	
If you answered YES to the question above, indicate the volume of financing raised in the last 3 years (grouped data from the 3 years):			
For the requirement put forth, please provide detailed information in relation to research, development of solutions, publications, etc., completed or being completed whose purpose is similar to that indicated.	Research. Detailed description. Development of solutions. Detailed description. Publications. Detailed description. Others. Detailed description.		
5. Description of the solution response			
Brief summary of the solution response: functional specification (maximum 1,250 characters) Description of the possible idea that could fulfill the requirement put forth, described from a functional approach. To provide more information on the idea, use appendices and identify them in the section 10 of the form.			
Estimated duration for the execution of the proposed response (months) Please determined the deadlines for each of the projection phases:	ail		
Estimated cost for the development of yo solution (euros) Please break down thamount by item:			
Economic contribution of the tenderer to the initiative (€, understanding as such the sum all contributions in means and resources the tenderer):	of of		
Indicate the impact that the development the proposed solution will general (healthcare, socioeconomic, profession and organizational):	te al		
Is the proposed project in line with yo business strategy? Explain which line ar how.			







Would your entity be interested in participating in the tender for this project?	
Does your entity have experience in developments related to the proposed project? What kind? (Please indicate for each project: year of execution, amount, brief description of results):	
Benefits provided by the proposed solution for other agents (max. 850 characters):	
6. I+D+i	
Innovation elements (new technologies deliver R&D results. Specifically, say what are the d compared to the products and services that a 850 characters):	ifferentiating elements of your proposal
Technological needs for the application of your proposal:	
Current maturity level at which your proposed solution is found (in case of knowing the technological maturity level (TRL1) where you are, indicate it):	
R&D results expected to be generated (max. 850 characters):	
Identify phases of integration with pre-existing technologies and services:	
Identify the phases of tests and trials (in real public service environments):	
Please indicate phases of validation, qualification, certification (eg FDA, IVD) and / or marking:	
Please indicate standards:	
Specifically, if so, in areas of urgency, emergencies, ICU.	
7. Deployment	
Please indicate the regulations and standards associated with the requirement put forth:	
Do you think there are any specific limitations or barriers to the deployment of the product on the market? Which?	

 $^{^{\}text{\scriptsize{1}}}$ TRL codes can be found in "HORIZON 2020 - WORK PROGRAM 2016-2017 General Annexes: G. TRL"







Is the scope of the proposed project clear and feasible?			
What characteristics of the project and the proposed scope do you consider to be more important?			
What are the main advantages found in the solution?			
What criteria do you consider important to evaluate the solution responses?			
In terms of Intellectual and Industrial Property Rights (IPR), a priori and due to the characteristics of your entity, does it have any limitations to sharing the IPR with the contracting agency or to establishing a royalty on future sales of the solution?	YES 🗆	NO	
If you answered YES to the question above, indicate what type? or if they do not exist, what percentage do you think could be shared with the contracting agency? What percentage of the sale price could be established as a royalty?			
What do you consider to be the main risks of the project?			
Do you intend to submit to future tenders related to the platform of artificial intelligence solutions based on Blg data for cancer screening in Andalusia (PIBICRA)?	YES 🗆 NO 🗆		
This information, or part of it, will be published in the conclusions of the Preliminary Market Consultation in order to promote collaboration between the participants, as well as these interested agents who have not participated in it.			
8. Mandatory Declarations			
I hereby authorize Consejería de Salud y Fan Emergencias Sanitarias to use the contents of exclusively limited to their possible inclusion in to faction, which will be specified in the possible contract procedures that are subsequently Procurement formula.	f the responses. This use the process of defining especifications for the	use will be g the lines ne possible	
The response submitted is free of copyright or of that prevents its unrestricted use by SAS or any in the development of future projects.			
9. Authorization to use the data provided			
Important: I authorize the Consejería de Sa Empresa Pública de Emergencias sanita disseminate contact data, to keep the necess or partial, on the proposal submitted accessib to disclose the information or technical commercial that, if applicable, is not identified rights of access, rectification, cancellation an	rias to store and ary information, total le and updated and documentation or das confidential. The		NO 🗆
exercised by contacting the following	• •		







<u>cpi.fps@juntadeandaluci</u>	a.es and info@equilinproject.com		
10. List of attached documentation provided			
If any, please indicate all documentation accompanying your response and providing more information on the idea.			
File name:	Brief description:	Confidentia	*

This information, or part of it, may be published in the conclusions of the Preliminary Market Consultation in order to encourage collaboration among participants, as well as interested parties that have not participated in it.

^{*}Please tick if the relevant documentation is confidential.